ArticleNature communications2025
Metabolomics of saliva, serum, and urine for pathogenesis, diagnosis, and prognosis in gestational diabetes mellitus.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gestational Diabetes Mellitus Across the Perinatal Continuum: A Narrative Review of Woman-Centered, Holistic Care Models.Healthcare (Basel, Switzerland) · 2026Review
- Identification of salivary lipid biomarkers for noninvasive diagnosis of reflux esophagitis via UHPLC-MS-based lipidomics.Metabolomics : Official journal of the Metabolomic Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Gestational diabetes mellitus (GDM) is a common metabolic disorder in pregnancy, but the underlying mechanism has not been fully clarified. Using metabolomic profiling of second-trimester saliva, serum, and urine, we identify 54 metabolites altered in GDM that converge on key metabolic pathways. Fifty GDM biomarkers independently associated with abnormal maternal glucose and insulin resistance are selected to construct GDM discriminant models (internal test AUC: 0.868; real-world test: 0.796). These GDM biomarkers are also associated with clinical profiles and adverse outcomes, thereby predicting maternal and neonatal risks (internal test AUC: 0.764 and 0.838; real-world test: 0.726 and 0.792, respectively). Eleven GDM biomarkers are already altered in the first trimester, which can be used for the early prediction of GDM (internal test AUC: 0.767; real-world test: 0.744). In this work, changes and interactions of metabolites in saliva, serum, and urine in the second trimester are first identified in GDM, providing insights into its pathogenesis and potential early prediction and prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.